A first case report of recurrent gastric cancer harboring a BRAFV600E mutation responding to dabrafenib plus trametinib
Comprehensive genomic profiling (CGP) has been increasingly implemented in clinical practice; however, only a limited proportion of patients ultimately receive genomically matched therapies. The BRAF V600E mutation is extremely rare in gastric cancer, and effective targeted treatment strategies remain undefined....